Compared with non-NPs administration, nanomaterial encapsulated drugs increased the half-life by 40 times, took advantage of EPR effect to accumulate drug concentration in the tumor, and increased the number of immune cells (CD4+ and CD8+ T cells) by 20 times. This evidence concerns the gene CD8A and neoplasm.